Several neoantigens result from recurrent chromosomal translocations in AML, e.g., PML-RARα, or gain-of-function mutations, e.g., FLT-ITD and NPM1, which renders them immunogenic target antigens [5,6,7,8]. Here, NPM1 is linked to acute myeloid leukemia.